Global Th17 Driven Disease Market Growth banking on Faster Regulatory Approvals for Key Drug Candidates

Award winning market research company Fact.MR’s ongoing study on the Th17 driven disease treatment market opines that the market is expected to embark on an optimistic growth path through 2021, as the global healthcare industry emerges from the recessionary impacts of the novel coronavirus pandemic.

The market is expected to enjoy robust growth over the coming years. Based on Indication Th17 Driven disease treatment market is classified into Psoriasis, Rheumatoid Arthritis, Multiple Sclerosis, Inflammatory Bowel Disease and Asthma. By the Drug type, Gentamicin, Azathioprine, Calcipotriol, Trolamine salicylate, Histamine and Capsaicin. By distribution channel, hospital pharmacies, is expected to dominate Th17 driven disease treatment market.

North America accounts for a significant revenue share, and is expected to dominate the Th17 driven disease treatment. This is attributed to the increasing prevalence of rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease and asthma. Countries like South Africa, Japan, Brazil, Germany and UK hold a significant market value share. Th17 driven disease treatment market in Asia Pacific is projected to expand at significant growth, driven by rapid regulatory approval for potential drug candidates. Rising government initiatives to increase awareness about the disease is stimulating growth of Th17 Driven disease treatment market.

Request Brochure at

Key Takeaways from Fact.MR’s Th17 Driven Disease Market Study

  • By indication, psoriasis treatment is expected to capture a high market share, amid its rising prevalence
  • Demand for azathioprine is likely to soar, owing to widespread application in treating rheumatoid arthritis
  • By distribution channel, hospital pharmacies to remain the primary Th17 driven disease drug suppliers
  • US to experience high drug sales on the back of surging cases of inflammatory bowel disease
  • Surging eczema cases to bolster Th17 driven disease drug sales across the UK market
  • Robust healthcare infrastructure is accelerating inflammatory disease treatment research across Germany
  • India to experience heightened investments in drug development research, amid rising cases of colitis and Crohn’s disease

Th17 Driven Disease Market- Prominent Drivers

  • Fast tracking of regulatory approvals of key drug candidates is heightening Th17 driven disease market growth prospects
  • Availability of multiple treatment alternatives to significantly widen growth prospects
  • Presence of a robust global supply chain network to accelerate R&D for new drug candidates, stimulating growth

Th17 Driven Disease Market- Key Restraints

  • Prolonged durations of clinical trials and subsequent waiting list regarding regulatory approvals is restricting growth
  • Expensive nature of available drugs owing to limited supply is limiting proper sales prospects for the market

Request Customization – 

Competitive Landscape

Prominent players in Th17 driven disease treatment market as profiled by Fact.MR’s report are AbbVie, Alexion Pharmaceuticals, Alder Biopharmaceuticals and Astellas Pharma. The aforementioned players are reliant on regulatory approvals for potential drug candidates. In addition, capacity expansion measures, including partnerships, collaborations and acquisitions are also relied upon.

Recently, in April 2021, AbbVie submitted regulatory applications for SKYRIZI® (risankizumab) for treating Psoriatic Arthritis to the US FDA and the European Medicines Agency (EMA). These submissions are supported by two phase 3 studies in patients with active psoriatic arthritis wherein the drug exhibited improved skin and joint symptoms and physical function.

With regard to acquisitions, UK pharmaceutical giant AstraZeneca announced in December 2020 that it intends to acquire Alexion Pharmaceuticals in order to broad base its scientific presence in immunology, and will also likely heighten the company’s portfolio of Th17 driven diseases treatment in the years to come.

More Insights on the Th17 Driven Disease Market

Fact.MR, in its new offering, brings to fore an unbiased analysis of the global Th17 driven disease market, presenting historical demand data (2016-2020) and forecast statistics for the period, 2021-2031. The study divulges compelling insights on the market based on indication (psoriasis, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease and asthma), drug (gentamicin, azathioprine, calcipotriol, trolamine salicylate, histamine and capsaicin) and distribution channel (hospital pharmacies, pharmacies and online pharmacies) across eight major regions (North America, Latin America, Western Europe, Eastern Europe, Asia Pacific, China, Japan and Middle East & Africa).

Explore Fact.MR’s Coverage on the Healthcare Domain: 

Leukocyte Count Testing Market – According to the latest research by Fact.MR, the leukocyte count testing market is set to witness exponential growth with over 7%-8% CAGR during 2021-2031. Increasing bacterial infection with the growing adoption of point of care devices will witness a promising growth outlook for leukocyte count testing in the long run.

At-Home Celiac Testing Market – According to the Latest Research by the Fact.MR The Celiac Testing market is set to gain growth in the forecast period 2021-2031 at a CAGR of 8.0%. The Reason for the growth is The increase in prevalence of Celiac disease globally.

Polysaccharide Hemostatic System Market – According to the latest research by Fact.MR, Polysaccharide Hemostatic System market is set to witness a XX% growth during the year 2021-2031.

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates

Visit Our Website: